White Plains Hospital

The trials here

What the 18 trials at this site are about, from their registry records.

Conditions

• Lung cancer7 trials
• Colorectal cancer3 trials
• Pancreatic cancer3 trials
• Endometrial cancer2 trials
• Melanoma2 trials
• Metastatic breast cancer2 trials
• Ovarian cancer2 trials
• Acute myeloid leukaemia1 trial
• Atrial fibrillation1 trial
• Bladder cancer1 trial
• Cervical cancer1 trial
• Chronic myeloid leukaemia1 trial
• and 7 more

Phase

• Phase 37 trials
• Phase 23 trials
• Phase 2/33 trials
• Phase 1/21 trial

Status

• Recruiting13 trials
• Completed3 trials
• Active, not recruiting2 trials

Lead sponsor

• BioNTech SE3 trials
• Pfizer3 trials
• Arbor Research Collaborative for Health1 trial
• Bristol-Myers Squibb1 trial
• Celcuity Inc1 trial
• and 9 more

Running trials

• Recruiting

  Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer

  NCT07578649· Phase 3· Pfizer· Source

• Recruiting

  A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

  NCT07365319· Phase 2/3· Eikon Therapeutics· Source

  Contact: Elelta Shiferraw

• Recruiting

  A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

  NCT07365995· Phase 3· BioNTech SE· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  NCT07144280· Phase 3· Pfizer· Source

• Recruiting

  A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

  NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source

  Contact: Dan Costin, Site 0285

• Recruiting

  A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

  NCT06875310· Phase 3· Mirati Therapeutics Inc.· Source

  Contact: Daniel Sammartino, Site 0618

• Recruiting

  Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

  NCT06712355· Phase 3· BioNTech SE· Source

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

  NCT06712316· Phase 2/3· BioNTech SE· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  NCT06330064· Phase 1/2· Daiichi Sankyo· Source

  Contact: Principal Investigator

• Recruiting

  The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

  NCT05836987· Phase 3· Johns Hopkins University· Source

  Contact: Aileen Ferrick

• Active, not recruiting

  Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

  NCT05501886· Phase 3· Celcuity Inc· Source

• Recruiting

  GEMINI-NSCLC: NSCLC Biomarker Study

  NCT05236114· Tempus AI· Source

  Contact: Madison Gilmore

• Recruiting

  Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

  NCT05184842· Phase 2· Montefiore Medical Center· Source

  Contact: Mendel Goldfinger, MD

• Recruiting

  Pancreatic Cancer Early Detection Consortium

  NCT04970056· Arbor Research Collaborative for Health· Source

  Contact: Griselda Cruz

• Active, not recruiting

  PF-07104091 as a Single Agent and in Combination Therapy

  NCT04553133· Phase 2· Pfizer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer6 recruiting
• Endometrial cancer2 recruiting
• Pancreatic cancer2 recruiting
• Acute myeloid leukaemia1 recruiting
• Atrial fibrillation1 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Colorectal cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Myelodysplastic syndromes1 recruiting
• Ovarian cancer1 recruiting
• Prostate cancer1 recruiting
• Stroke1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  Phase 2 Study of DKN-01 in Colorectal Cancer

  NCT05480306· Phase 2· Leap Therapeutics, Inc.· Source

• Completed

  Prevention of Colorectal Cancer Through Multiomics Blood Testing

  NCT04369053· Freenome Holdings Inc.· Source

• Completed

  Pancreatic Cancer Early Detection Program

  NCT02206360· White Plains Hospital· Source